1 Antagonists of glutamate N-methyl-D-aspartate (NMDA) subtype receptor inhibit the development of tolerance to the antinociceptive eects of opioids. Another way to inhibit the function of glutamate receptors is the stimulation of presynaptic metabotropic group II (mGluRII) receptors. Because LY354740 ((+)-2-aminobicyclo [3,1,0] hexane-2,6-dicarboxylic acid) is the ®rst systemically active agonist of group II mGlu receptors, we investigated if this compound might inhibit the development of tolerance to antinociceptive eects of morphine and fentanyl. 2 As assessed by cumulative dose-response approach in the tail-¯ick test, administration of 10 mg kg 71 morphine bid s.c. to male Albino Swiss mice for 6 days, right-shifted morphine doseresponse curve by *4 fold. In a separate group of mice, 12 injections of 0.04 mg kg 71 of fentanyl over 3 days, right-shifted fentanyl dose-response curve by *3.3 fold. 3 In experiment 1, LY354740 (1 and 10, but not 0.1 mg kg 71 ) as well as the reference compound, an uncompetitive NMDA receptor antagonist memantine (7.5 mg kg 71 ) inhibited the development of morphine tolerance. Neither LY354740 (10 mg kg 71 ) nor memantine (7.5 mg kg
Introduction
Glutamate, the major excitatory neurotransmitter of the brain, stimulates both ionotropic and metabotropic glutamate receptors (Monaghan et al., 1989; Conn & Pin, 1997) , and plays a signi®cant role both in physiology and pathophysiology of the central nervous system (Danysz et al., 1995a) . Converging lines of evidence (reviewed by Bisaga & Popik, 2000) indicate substantial involvement of glutamate receptors in phenomena related to opioid tolerance and dependence. For example, antagonists of the N-methyl-D-aspartate (NMDA) receptor complex attenuate the development (Trujillo & Akil, 1991; Marek et al., 1991) , expression (Cappendijk et al., 1993) and maintenance (Popik & Skolnick, 1996) of the ongoing morphine dependence. Recent work demonstrates similar eects of the agonist of metabotropic group II receptors (mGluRII), LY354740, that inhibits the expression of morphine dependence in mice (Klodzinska et al., 1999) and rats (Vandergri & Rasmussen, 1999) .
A phenomenon related to drug dependence is drug tolerance. Tolerance to the antinociceptive eects of m-agonist morphine, the most widely used opioid analgesic, greatly limits its therapeutic ecacy and thus complicates the management of patients with chronic pain. The development of tolerance to opioid antinociception is manifested as a shift to the right of the dose-response curve or as a decrease in the intensity of the response when a constant dose is repetitively administered (Foley, 1991) . In laboratory animals, antinociceptive (analgesic) tolerance is usually assessed as a decrease in response in the presence of a constant nociceptive stimulus (Cochin & Kornetsky, 1964) . The inhibition of glutamatergic transmission by means of the use of NMDA receptor antagonists is known to inhibit the development of morphine tolerance. In the mouse, such eects have been shown for the uncompetitive NMDA receptor antagonists, (+)MK-801 (dizocilpine) (Lutfy et al., 1993; Elliott et al., 1994a; Bilsky et al., 1996; Gonzalez et al., 1997; Belozertseva & Bespalov, 1998) , memantine (Belozertseva & Bespalov, 1998; Popik & Kozela, 1999; Popik et al., 2000) , dextromethorphan (Elliott et al., 1994b; and ketamine (Gonzalez et al., 1997) , the glycine/ NMDA receptor antagonist ACEA-1328 (Lutfy et al., 1995) as well as the competitive NMDA receptor antagonists, LY274614 (Elliott et al., 1994a) , LY235959 (Bilsky et al., 1996) and CGP 39551 (Gonzalez et al., 1997) . However, the eects of mGluRII agonists on morphine tolerance have not been investigated, perhaps due to the lack of selective pharmacological tools, which would penetrate into the brain.
Metabotropic glutamate receptor subtypes (1 ± 8) are classed in three groups based on sequence homology, signal transduction mechanism and pharmacology. The discovery of (+)-2-aminobicyclo [3,1,0] hexane-2,6-dicarboxylic acid (LY354740), which selectively and potently (EC 50 10 ± 50 nM) stimulates human recombinant and native rat mGlu group II receptors, and is the ®rst agonist of this class of receptors that penetrates into the brain Bond et al., 1997) , has oered a valuable tool to study its central eects following systemic administration to animals. The behavioural eects of LY354740 are characterized to some extent. This compound produces anxiolytic eects in the fear potentiated startle and elevated plus maze models of anxiety (Helton et al., 1998) and at doses of 0.5 ± 1 mg kg 71 appears to produce anxiolytic eects in the Vogel test (Klodzinska et al., 1999) . Similar anxiolytic eects (4 ± 8 mg kg
71
) were shown in a four-plate test (Klodzinska et al., 1999) . Administration of LY354740 at the dose of 8 mg kg 71 produced 55% reduction in the spontaneous locomotor activity in mice but did not disturb the locomotor coordination on the rota-rod test (Helton et al., 1998; Klodzinska et al., 1999) . LY354740 did not show anỳ antidepressive' eects in rodents, but at doses of 0.15 ± 5 mg kg 71 inhibited naloxone-precipitated morphine withdrawal in morphine-dependent mice (Klodzinska et al., 1999) .
The present experiments were carried out in order to investigate whether LY354740 may in¯uence the development of morphine tolerance. Because of the report demonstrating that NMDA receptor antagonists inhibit antinociceptive tolerance produced by morphine but not selective m-or dopioid agonists (Bilsky et al., 1996) , the eects of LY354740 and memantine on antinociceptive tolerance produced by a selective m-receptor agonist, fentanyl, were also studied.
Methods

Subjects
Male Albino Swiss mice obtained from our Institute breeding stock and weighing 25 ± 30 g at the start of the experiment were used. Mice were group-housed in the standard laboratory cages and kept in a temperature-controlled colony room (21+28C) with a 12-h light/dark cycle (light on: 0700 ± 1900 h). Commercial food and tap water were available ad libitum. Each experimental group consisted of 8 ± 20 mice per dose. All mice were used only once.
Analgesia apparatus and testing
A standardized tail-¯ick apparatus (Analgesia Meter, Innovators in Instrumentation, NJ, U.S.A., model 33), set with adjusted sensitivity at six and break point at 84 ± 85 with radiant heat source and connected to an automatic timer was used to assess antinociceptive response. The intensity of the heat stimulus was adjusted so that the baseline tail-¯ick latency was *3.6 s. A maximum latency of 10 s (i.e., cut-o) was used to minimize damage to the tail. The tail¯ick withdrawal latency was measured from the start of the heat stimulus applied to the distal 2 cm of the tail until the animal exhibited a¯ick of the tail. Two tail-¯ick responses were recorded for each mouse and each dose (Paronis & Holtzman, 1991) .
Morphine or fentanyl cumulative dose-response curves were used to reduce the number of animals required to assess the development of morphine tolerance (Paronis & Holtzman, 1991) . After adaptation and baseline trials, each mouse was injected s.c. with a low dose of morphine (1 mg kg 71 ). Thirty minutes later, the mouse was retested and injected with the next dose of morphine, such that the cumulative dose was increased by 0.25 log unit. Thus, because the initial dose of morphine was 1.0 mg kg 71 , the next dose was 1.78 mg kg
71
, for a cumulative dose of 2.8 mg kg
71 . This procedure continued until either the mouse did not move his tail within the cut-o time or until there was a plateauing of the doseresponse curve, so that the latency did not increase from one dose to the next. Each analgesic responder was not subjected to further tail¯ick assessments but was injected with the subsequent dose of morphine so that each animal received the same total dose of morphine during a given test.
The construction of cumulative fentanyl dose-response curves was carried out similarly to the measurement of morphine antinociceptive eects with the exception that the doses of fentanyl started with 0.0022 mg kg 71 , increased by 0.5 log unit, and were performed in 15 min intervals (Paronis & Holtzman, 1991) .
Comparison of morphine and fentanyl cumulative doseresponse curves obtained on days 1 and 8 as well as days 1 and 5, respectively, were used to assess the extent of morphine tolerance.
Design of the experiments
Experiment 1 was designed to determine if LY354740 and memantine could inhibit the development of tolerance to the antinociceptive eects of morphine and fentanyl. On day 1, the ®rst antinociceptive measurement was performed, followed by 6 days of twice daily morphine injections (10 mg kg 71 , s.c.) (Elliott et al., 1994a) . The pretreatment with LY354740 (0.1, 1 or 10 mg kg 71 ) and memantine (7.5 mg kg
71
) was given 30 min prior to each morphine dose on days 2 ± 7 of this experiment.
Because of the report demonstrating that NMDA receptor antagonists inhibit antinociceptive tolerance produced by morphine but not selective m-or d-opioid agonists (Bilsky et al., 1996) , in the parallel experiment, we investigated the eects of LY354740 (10 mg kg 71 ) and memantine (7.5 mg kg 71 ) pretreatment on antinociceptive tolerance produced by magonist, fentanyl. The dose of 0.04 mg kg 71 of fentanyl was selected based on the preliminary experiment, which demonstrated that in our experimental setup fentanyl ED 50 dose is *0.02 mg kg
. The pretreatment with LY354740 and memantine was given 30 min before each of the fentanyl injections on days 2 ± 4 of this experiment. Mice were treated four times per day, between 0800 and 2000 h, in 4 h intervals, because previous studies demonstrated that fentanyl has a shorter duration of action and more rapid elimination kinetics than morphine (Bilsky et al., 1996; Walker et al., 1997) . As suggested (Walker et al., 1997) , in order to keep the number of injections equal to the number of morphine injections, only 3 days of fentanyl treatment were given (i.e., 12 injections).
Experiment 2 was designed to determine whether LY354740 and memantine might produce their own antinociceptive eects and/or, change the antinociceptive eects of morphine. Morphine (5 mg kg 71 , s.c.) was administered 30 min after injection of LY354740 (1 or 10 mg kg 71 ), memantine (7.5 mg kg 71 ), or placebo.
Data presentation and statistics
Latencies (in sec) of the tail-¯ick responses were converted to MPEs [Maximum Percent Eects (Paronis & Holtzman, 1991) ], according to the formula: 1006 [(post-injectory latency ± baseline latency)/(cut-o latency ± baseline latency)].
MPE values were used to construct morphine and fentanyl cumulative dose-response curves by non-linear regression; these curves were used to calculate antinociceptive ED 50 values using GraphPad Prism ver. 3.00 (GraphPad Software, CA, U.S.A.) software. The ED 50 values obtained on test #1 were compared among groups, as were the fold shifts (determined by dividing individual test #2 ED 50 values by the test #1 ED 50 values).
In the experiment 2, eects of compounds on tail¯ick responses were compared with the use of area under curve (AUC) assessments, which were calculated using trapezoid rule (Delta X * (Y1+Y2)/2) on a series of measurements from 0 ± 120 min. Statistical analyses involved one way between subjects ANOVA followed by Newman-Keul's test. P50.05 was considered signi®cant. 
Drugs
Results
Eects of LY354740 and memantine on the development of tolerance to morphine and fentanyl (experiment 1) ) aected the development of morphine tolerance, since the fold changes were 2.7 and 2.5, respectively (Table 2) . ) determined during pre-and post-morphine-tolerance development tests as well as resulting fold changes. The tolerance was induced by 10 mg kg ±1 s.c. bid morphine administration over 6 days. LY354740, memantine or placebo was given s.c. 30 min prior to each of the morphine injections. Asterisks indicate a statistically signi®cant dierence toward`control' group that received placebo+morphine during the development of morphine tolerance (*P<0.05, **P<0.01, Newman-Keul's test). Presented are mean antinociceptive fentanyl ED 50 +s.e.mean values (mg kg ±1 ) determined during pre-and post-fentanyl-tolerance development tests as well as resulting fold changes. The tolerance was induced by 0.04 mg kg ±1 s.c. qid fentanyl administration over 3 days. LY354740, memantine or placebo was given s.c. 30 min prior to each of the fentanyl injections. Asterisks indicate a statistically signi®cant dierence toward`control' group that received placebo+placebo during the development of fentanyl tolerance (*P<0.05, **P<0.01, Newman-Keul's test).
mGluRII agonist inhibits morphine tolerance
Eects of LY354740 and memantine on the tail-¯ick response and antinociceptive eects of morphine (experiment 2)
As the ®rst injection, four groups of mice were treated with LY354740 (1 or 10 mg kg 71 ), memantine (7.5 mg kg 71 ) or placebo, and the one drug-free control group was treated with placebo. Tail-¯ick responses were determined 30 min after the ®rst injection to determine whether LY354740 or memantine altered the tail¯ick response. Immediately later these mice were injected with 5 mg kg 71 of morphine and a separate drug-free group was injected with placebo (second injection).
With regard to the acute antinociceptive eects, there were no signi®cant dierences among groups (one way ANOVA: F(4,40)=1.591, P40.05, (Figure 1,`time 0' ). The data gained at 30 min after the second injection were analysed with one way ANOVA which yielded signi®cant dierences among groups: F(4,40)=16.53, P50.0001, (Figure 1,`time 30' ). The post-hoc analysis with the use of Newman-Keul's test revealed that compared to placebo+morphine group, memantine+-morphine and placebo+placebo groups demonstrated signi®cantly shorter tail-¯ick responses (P50.05 and P50.001, respectively). At 60 min after second injection: F(4,40)=9.52, P50.0001, (Figure 1 ,`time 60'), there was a dierence (P50.01) between placebo+morphine and placebo+placebo treated mice. This dierence (P50.05) persisted until 90 min after second injection F(4,40)=5.365, P50.01, (Figure 1 ,`time 90'), but was not apparent at 120 min after second injection.
The overall eects of various treatments on tail-¯ick responses assessed on AUC data demonstrate that the only placebo+placebo treatment diered signi®cantly (P50.01, Newman-Keul's test followed one way ANOVA F(4,40)=9.31, P50.0001) from placebo+morphine treatment (Figure 1, inset) .
Discussion
The present ®ndings demonstrate that LY354740, the ®rst systemically active agonist of group II mGlu receptors as well as memantine, a clinically available low anity uncompetitive NMDA receptor antagonist, may inhibit the development of tolerance to antinociceptive eects of morphine but not of fentanyl. Neither LY354740 nor memantine aected the tailick antinociceptive response or the acute antinociceptive eect of morphine. Group II mGlu receptors are localized presynaptically and to a lesser extent, postsynaptically (Petralia et al., 1996; Shigemoto et al., 1997) and are therefore regarded as autoreceptors (Ugolini & Bordi, 1995) . It has been demonstrated that the activation of presynaptic mGlu receptors localized on glutamatergic nerve terminals causes a decrease in glutamate release both in vitro (Attwell et al., 1995; 1998a,b) and in vivo (Battaglia et al., 1997) . Therefore, stimulation of presynaptic group II mGluR autoreceptors may produce the functional antagonism of the glutamatergic system (Lovinger & McCool, 1995) and thus, may inhibit glutamatergic excitatory transmission (for the reviews, see Glaum & Miller, 1994; Pin & Duvoisin, 1995) .
The inhibitory eects of NMDA receptor antagonists on morphine tolerance in mice as shown in experiment 1 has been previously demonstrated by other investigators (Lutfy et al., 1993; Elliott et al., 1994a; Bilsky et al., 1996; Gonzalez et al., 1997; Belozertseva & Bespalov, 1998 as well as in our Figure 1 Time course of the tail-¯ick test responses of mice treated with a combination of LY354740 or memantine and morphine. Placebo or morphine (5 mg kg 71 ) was administered s.c. 30 min after injection of LY354740, memantine or placebo. Data are expressed as means+s.e.mean %MPE. n=0, 8, 9, 9, and 9 for placebo+morphine, placebo+placebo, 10 mg kg 71 of LY354740+morphine, 1 mg kg 71 of LY354740+morphine and 7.5 mg kg 71 of memantine+morphine, respectively. For other details, see text. Inset: Presented are mean+s.e.mean Area Under Curve (AUC) values calculated on the same data. One way ANOVA F(4,40)=9.31, P50.0001 and post-hoc Newman-Keuls test revealed that the treatment with placebo+morphine diered signi®cantly (**, P50.01) only towards placebo+placebo treatment. mGluRII agonist inhibits morphine tolerancelaboratory (Popik & Kozela, 1999; Popik et al., 2000) . However, the eects of mGlu II receptors agonist in this respect were unknown and deserve an explanation.
There are several hypotheses that may explain the inhibitory eects of LY354740 on morphine tolerance. First, the development of drug tolerance represents a neuronal plastic change and thus resembles learning processes (Siegel, 1976) . Given the fact that NMDA receptor antagonists interfere with learning processes (see Danysz et al., 1995b for the review), it is possible that the compounds used in the present study might attenuate the development of morphine tolerance through the inhibition of neuronal plasticity. This hypothesis is particularly attractive in light of the recent ®ndings demonstrating that prolonged morphine administration may further increase the inhibitory eect of group II mGlu receptor agonists on glutamate release (Martin et al., 1999) . Since, in addition, presynaptic mGlu receptor agonists are thought to inhibit NMDA receptor function (Glaum & Miller, 1994; Pin & Duvoisin, 1995) , it can be hypothesized that the inhibitory eects of both LY354740 and memantine on morphine tolerance are related to an inhibition of neuronal, glutamatedependent plasticity. However, the eects of memantine and LY354740 on the tolerance appear unrelated to their purported`amnestic' eects. This is because LY354740 did not produce learning impairment (Helton et al., 1998) , and the doses of memantine aecting learning processes are much above doses used in the present study. For example, while memantine signi®cantly attenuated the development of morphine tolerance at a dose of 7.5 mg kg 71 , data from this laboratory indicate that the same dose did not impair the acquisition of spatial learning (Popik & Danysz, 1997) . Similarly, in a continuous multiple-trial two-choice dark avoidance paradigm, memantine impaired learning at the dose of 20 mg kg 71 but not 10 mg kg 71 (Misztal & Danysz, 1995) . It is possible that an interaction between LY354740 and morphine occurred at the level of second messengers and/or receptors aected by both compounds. With regard to the additive action directly at the level of opioid receptors, we found no data in the literature concerning reasonable anity of LY354740 at opioid receptors. Moreover, data from experiment 2 demonstrate the lack of antinociceptive eect of LY354740, suggesting that this compound is unlikely to act at the level of opioid receptors.
At the level of second messenger systems, like opiates (Duman et al., 1988) , mGluRII agonists inhibit adenylate cyclase activity that produces an inhibition of cyclic AMP accumulation in the brain (Schoepp et al., 1992; Schahauser et al., 1997) . However, the inhibitory eects of LY354740 on the development of morphine tolerance are unlikely explained by its eect on cyclic AMP system, because both LY354740 and morphine appear to aect the generation of this second messenger in the same direction. Moreover, if such a direct interaction would occur in vivo, LY354740 would potentiate the acute antinociceptive eects of morphine, which was not the case (experiment 2). It cannot be excluded however that the present experimental setting, which employed discrete, intermittent injections of morphine, in fact produced multiple withdrawal states resulting in an increase in the basal pain sensitivity and thus giving an impression of apparent tolerance (Laulin et al., 1999) . It is known that prolonged inhibition of cyclic AMP system by opiates may led to an up-regulation of cyclic AMP system (Duman et al., 1988) which may form the basis of opiate dependence and tolerance (Nestler, 1993) . It is also known that both LY354740 (Schoepp et al., 1992; Schahauser et al., 1997 ) and e.g., clonidine (Duman & Enna, 1986) inhibit adenylate cyclase activity and that both compounds attenuate symptoms of opiate withdrawal (Klodzinska et al., 1999; Vandergri & Rasmussen, 1999; Gold et al., 1978) . Therefore, it can be speculated that compounds that counteract an up-regulation of cyclic AMP system caused by chronic morphine administration and/or inhibit the cyclic AMP system despite its up-regulation, may attenuate morphine-induced tolerance produced by discrete, intermittent administration of opiates.
Finally, there is also a possibility that prolonged treatment with LY354740 might cause induction of liver enzymes, which in turn could increase the hepatic metabolism of morphine, giving an impression of morphine tolerance. Although without speci®c studies this hypothesis cannot be ruled out unequivocally, it appears unlikely in light of studies indicating that LY354740 is eliminated primarily by renal clearance in both rats and dogs .
The failure of pretreatment with eective doses of LY354740 and memantine to inhibit the development of fentanyl tolerance con®rms and extends previous ®ndings demonstrating that uncompetitive and competitive NMDA receptor antagonists inhibit antinociceptive tolerance produced by morphine but not selective m-or d-opioid agonists (Bilsky et al., 1996) . To explain the inhibitory eects of NMDA receptor antagonists on morphine tolerance and ineectiveness of these compounds to aect fentanyl tolerance, (Bilsky et al., 1996) noted several dierences regarding tolerance to morphine and more speci®c m-opioid agonists. These include: (1) the fact that morphine is less selective at mopioid receptors than fentanyl; (2) the hypothesis implying dierent states or mechanisms of tolerance produced by morphine and speci®c m-receptor agonists; (3) the notion that morphine is a partial agonist at the opioid m-receptors, while fentanyl may have higher ecacy and, (4) dierences in pharmacokinetics between morphine and fentanyl. Other hypotheses may include dierences in internalization and phosphorylation of m-receptors produced by morphine and more selective m-opioid receptor agonists. Our data demonstrating that neither memantine nor LY354740 aected tolerance to the antinociceptive eects of fentanyl point to the conclusion that the inhibitory eect of mGluRII agonist on morphine tolerance is similar to the eect of NMDA receptor antagonist(s). It appears intriguing that despite profound dierences in the molecular mechanism of action of LY354740 and memantine, these compounds seem to produce essentially the same eects on morphine and fentanyl antinociceptive tolerance. At present, the only hypothesis that may be proposed to explain this similarity would imply that mGluRII agonist inhibited morphine tolerance by decreasing the function of NMDA receptor via the inhibition of glutamate release (Glaum & Miller, 1994; Pin & Duvoisin, 1995) .
In conclusion, the present study demonstrates that LY354740 and memantine inhibit the development of the tolerance to the analgesic eects of morphine without aecting nociceptive response per se or interfering with morphine analgesia. These ®ndings indicate the therapeutic potential of metabotropic glutamate group II agonists in the management of chronic pain.
